REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in Stock

REGENXBIO Inc. (NASDAQ:RGNX) Director Kenneth T. Mills sold 20,602 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director now directly owns 475,103 shares in the company, valued at $3,758,064.73. This represents a 4.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

REGENXBIO Price Performance

NASDAQ RGNX opened at $8.89 on Friday. The business has a fifty day moving average price of $7.54 and a two-hundred day moving average price of $7.98. REGENXBIO Inc. has a fifty-two week low of $5.04 and a fifty-two week high of $16.25. The stock has a market capitalization of $445.54 million, a PE ratio of -1.77 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.29). The business had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, sell-side analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RGNX. Morgan Stanley increased their price target on REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, March 14th. HC Wainwright reduced their price target on REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, March 17th. The Goldman Sachs Group reduced their price target on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Finally, StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.63.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its holdings in shares of REGENXBIO by 67.0% during the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock worth $31,975,000 after buying an additional 1,659,206 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of REGENXBIO by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company’s stock worth $24,832,000 after buying an additional 487,036 shares in the last quarter. Millennium Management LLC increased its holdings in shares of REGENXBIO by 406.3% during the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock worth $10,222,000 after buying an additional 1,061,187 shares in the last quarter. Balyasny Asset Management L.P. increased its holdings in shares of REGENXBIO by 6.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company’s stock worth $9,176,000 after buying an additional 66,993 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of REGENXBIO by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company’s stock worth $9,054,000 after buying an additional 21,234 shares in the last quarter. 88.08% of the stock is currently owned by institutional investors and hedge funds.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.